Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App




POC Analyzer Compared with HPLC Method

By LabMedica International staff writers
Posted on 20 Jun 2017
The measurement of the glycated fraction of hemoglobin (HbA1c) has been recommended to diagnose diabetes, in addition to monitoring glycemic control. More...
HbA1c reflects long-term glycemic control over the preceding two to three months as opposed to glycemic control at a single point in time.

Point of Care Testing (POCT) enables measurement of HbA1c in a clinical setting without the waiting time associated with laboratory testing or the high level of expertise required; however, for POCT methods to be used effectively they must be comparable to those used in a clinical laboratory.

Scientists at Swansea University assayed EDTA blood samples from 100 subjects with and without diabetes. HbA1c was determined using the BioRad D10 high performance liquid chromatography (HPLC) analyzer as the laboratory reference method and the Quo-Test POCT analyzer. The BioRad D10 required 10 μL and the Quo-Test 4 μL of whole blood. Quality control was carried out every day of testing using BioRad Lyphocheck Hemoglobin A1C Controls for the D10 and EKF Diagnostics Quo-Test A1c Controls for the Quo-Test.

The investigators found a median HbA1c was 60 mmol/mol (Interquartile range (IQR) 44.0–71.2) (7.6% (6.17–8.66)) and 62 mmol/mol (45.0–69.0) (7.8% (6.27–8.46) for D10 and Quo-Test, respectively, with very good agreement. Mean (range) intra- and inter-assay variation was 1.2% (0.0–2.7%) and 1.6% (0.0–2.7%) for the D10 and 3.5% (0.0–6.7%) and 2.7% (0.7–5.1%) for the Quo-Test. Mean change in HbA1c after 28 days storage at −20 °C was −0.7% and +0.3% for D10 and Quo-Test respectively. Compared to the D10, Quo-Test showed 98% agreement for the diagnosis of glucose intolerance, impaired glucose tolerance and type 2 diabetes mellitus (T2DM) and 100% for the diagnosis of T2DM.

The authors concluded that the performance of the Quo-Test POCT analyzer is similar to that of a laboratory HPLC analyzer and good agreement was found between the D10 and Quo-Test and seen across a wide HbA1c range. The Quo-Test POCT analyzer should be considered for diagnostic purposes by the various professional organization that issue clinical guidelines. The study will be published in the August 2017 issue of the journal Practical Laboratory Medicine.


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.